A large number of diverse functions have been attributed to the BRCA1 and BRCA2 breast cancer susceptibility genes. Here we review recent progress in the field.
Introduction
About one in ten women in the Western world develop cancer of the breast and at least 5% of these cases are thought to result from a hereditary predisposition to the disease [1] . Two breast cancer susceptibility (BRCA) genes have been mapped and cloned (Figure 1 ), and mutations in these genes underlie the disease in most families in which four or more cases of breast cancer are diagnosed in women below the age of 60. Women who inherit loss-offunction mutations in one allele of either of these genes have an up to 85% risk of breast cancer by age 70. Both BRCA1 and BRCA2 are thought to be tumour suppressor genes as the wild-type allele of the gene is lost in tumours of heterozygous carriers. As well as breast cancer, carriers of mutations in these genes are at elevated risk of cancer in the ovary, prostate and pancreas. Surprisingly, despite the association with inherited predisposition, somatic diseasecausing mutations in BRCA1 and BRCA2 are extremely rare in sporadic breast cancers. Functions for the BRCA proteins in a bewildering array of biological processes have been suggested [2] . But whether dysfunction of all or only a subset of these processes contributes to cancer initiation or progression is unknown. Here we discuss recent new findings on the functions of BRCA1 and BRCA2 which provide more detail on their potential roles in transcriptional regulation and DNA repair and suggest additional roles in processes such as polyadenylation of mRNA and protein degradation.
Fixing DNA
Both BRCA1 and BRCA2 have been consistently linked to various processes of the repair of damaged DNA. These Functional domains in the BRCA1 and BRCA2 proteins. The RING finger is a protein-protein interaction domain which may have ubiquitin ligase activity. The BRCT domain is another protein-protein interaction motif which is found principally in proteins involved in DNA metabolism or repair. BRCA2 contains nine separate potential RAD51 binding domains -8 BRC repeats and a structurally independent carboxy-terminal domain. Both BRCA1 and BRCA2 contain nuclear localisation sequences (NLS).
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include the repair of double-strand breaks by homologous recombination and the repair of oxidative damage by transcription-coupled repair [3, 4] . Now several new papers provide further insight into the potentially multi-purpose role of BRCA proteins in DNA repair.
Mammalian cells repair breaks in double-stranded DNA by non-homologous end joining or by homologous recombination [5, 6] (Figure 2 ). Substantial evidence is now available for a role for both BRCA1 and BRCA2 in homologous recombination. Both BRCA1 and BRCA2 can interact directly or indirectly with RAD51 [7] [8] [9] [10] , the eukaryotic equivalent of bacterial RecA. RAD51 catalyses strand exchange during homology directed repair of DNA doublestrand breaks by gene conversion. Within BRCA2, the RAD51 interaction is mediated by a number of repeats of a specific sequence -the BRC repeat -and an unrelated domain located at the carboxy terminus ( Figure 1 ) [7, 9, 10] . BRC repeats may regulate the loading of RAD51 onto DNA [11] . Taken together with the colocalisation of BRCA1 and BRCA2 with RAD51 in ionising radiation induced nuclear foci [10] , these observations suggest a role for BRCA1 and BRCA2 in DNA repair by homologous recombination. Furthermore, mouse and human BRCA1 and BRCA2 mutant cells suffer from chromosome instability [12] [13] [14] [15] [16] [17] and have a heightened sensitivity to DNA lesions that are repaired by homologous recombination [14, [18] [19] [20] [21] .
A direct and elegant analysis of the ability of BRCA1 and BRCA2 mutant cells to repair double-strand breaks created by endonucleases has been performed by Jasin and colleagues [22] . Mouse embryonic stem (ES) cells lacking BRCA1 are deficient in the repair of double-strand breaks by homologous recombination [23] . Similarly, ES cells with disruptions in BRCA2 are compromised for repair of double-strand breaks by gene conversion [24] . Loss of BRCA2 appears to result in alternative use of the errorprone single strand annealing pathway (Andrew Tutt, personal communication). Use of error-prone pathways instead of BRCA1 and 2 dependent conservative routes to repair is likely to create considerable genome instability and may contribute to loss of tumour suppressor genes and tumorigenic progression.
Models have been proposed to explain the roles of BRCA1 and BRCA2 in the maintenance of chromosome instability through functions in DNA replication [4] . Stalled replication forks caused by a variety of mechanisms such as base lesions, DNA breaks or strand gaps, are thought to require homologous recombination to restart replication. If homologous recombination is dysfunctional then stalled replication forks may lead to persistent DNA breaks and ultimately to gross chromosomal rearrangements including translocations. These are indeed frequently seen in cells lacking BRCA1 and BRCA2 [12] [13] [14] [15] [16] [17] . Such rearrangements may well provide the raw material for the further genetic changes required for tumour progression.
BACH variations
A recent paper [25] from David Livingston's group describes the isolation of BACH1, a novel putative DNA helicase which interacts with the BRCT domains of BRCA1. BACH1 contains substantial sequence similarity to the catalytic and nucleotide binding domains of known members of the DEAH helicase family which includes the Xeroderma Pigmentosum complementing group D (XPD) protein [26] [27] [28] . BACH1 binds to BRCA1 and, as helicases have been implicated in DNA repair, the authors [25] asked whether BACH1 has such a function. They expressed a dominant negative mutant of BACH1 in tissue culture cells and, by measuring the rate of double-strand break Although mutations in BRCA1 and BRCA2 account for a significant proportion of early onset familial cancers, it is clear that other BRCA genes exist [29] . To test whether BACH1 might be a novel BRCA gene, Livingston and colleagues [25] surveyed a series of breast cancer families and early onset breast cancers which were devoid of mutations in BRCA1 and 2. Two heterozygous missense mutations were identified in BACH1 in germline DNA of two breast cancer patients. Both these sequence differences resulted in amino acid changes (P47A and M299I) in the helicase domain of BACH1 and were thought unlikely to be common polymorphisms. And both were discovered in early onset breast cancer patients, one of whom, the carrier of the P47A change, had a strong family history of breast and ovarian cancer. Unfortunately the authors were unable to confirm segregation of this mutation with breast cancer, as the appropriate DNAs were not available. Furthermore, the wild-type allele appeared to be retained in the tumour genome.
So how might these changes result in early onset breast cancer? To address this question, mutant and wild-type versions of BACH1 were expressed ectopically in U20S cells [25] . Interestingly, the P47A mutation appeared to lead to destabilisation of the BACH1 protein.
In the absence of evidence that the other allele of BACH1 is affected in the tumour carrying the P47A mutation, the authors speculate that haploinsufficiency could contribute to tumour formation in early onset breast cancer. However, without definitive genetic evidence it is premature to ascribe a significant role to BACH1 in familial breast cancer and it remains possible that the sequence changes are rare polymorphisms.
The Fanconi connection
Fanconi's anemia is an autosomal recessive disorder characterised by cancer susceptibility, congenital abnormalities and bone marrow failure [30] . Patients with this disease develop several types of cancer but are particularly prone to acute myeloid leukemias and squamous cell carcinomas of the head and neck. The cells of these patients are characterised by chromosomal instability and enhanced sensitivity to bifunctional alkylating agents that cross-link DNA. Six different genes, FANC1-6, have been shown to be mutated in patients with Fanconi's anemia but little is known about their function or how their mutation leads to the disease [30] . Recently, a new Fanconi's anemia gene, FANCD2, has been isolated [31] . The demonstration that the product of FANCD2 interacts with BRCA1 may provide new insights into both Fanconi's anemia and breast cancer susceptibility [32] . FANCD2 becomes modified by the addition of a single ubiquitin residue in response to DNA damage [32] ; this monoubiquitination is distinct from that generally observed when proteins are targeted for degradation (see below). Coincident with the ubiquitin modification, FANCD2 becomes localised to nuclear foci which, after further examination, were also found to contain BRCA1. Additional support for a functional interaction comes from observations that BRCA1 and FANCD2 can be coimmunoprecipitated from gamma-irradiated cells.
The importance of ubiquitination in the localisation of FANCD2 and the suggestion that BRCA1 has ubiquitin E3 ligase activity [33] [34] [35] suggests an obvious mechanism by which BRCA1 regulates FANCD2. Intriguingly radial aberrations typical of Fanconi's anemia are observed in both BRCA1 and BRCA2-null cells [14, 15] .
BRCA1 breaks down
Protein degradation is increasingly being recognised as a key step in the regulation of embryonic development and cell growth and differentation. Abnormal regulation of protein degradation is also critical to the pathogenesis of neurodegenerative diseases and cancer. One of the first features of the BRCA1 protein to be described was the RING finger domain (see Figure 1 ), although at the time the function of this domain was not clearly understood. Indeed RING fingers were thought capable of interacting with DNA. Recently, the RING domain has been implicated in the ubiquitin-mediated proteolytic pathway.
A key cellular pathway for protein degradation is mediated by polyubiquitination of specific lysine residues; polyubiquitinated substrates are degraded by the 26S proteosome [36] . The ubiquitin E3 ligase catalyses the formation of polyubiquitin chains on substrate proteins via iso-peptide bonds using ubiquitin that has been activated by enzymes E1 and E2 ( Figure 3 ). Specific ligase complexes are associated with regulation of specific cellular processes. For example, the Skp1-Cullin-F box complex, SCF, and the cyclosome or anaphase promoting complex, APC, are the two major ubiquitin ligase complexes that regulate ubiquitin-mediated proteolysis during G1/S and anaphase, respectively [37] . Recently several RING finger proteins, with otherwise diverse structures, such as c-CBL, IAP, and MDM2 have been linked to ubiquitination of important regulatory proteins [33, [38] [39] [40] . Now BRCA1 has been suggested to function in ubiquitination [33] [34] [35] . Although the BRCA1 RING domain alone has low E3 ubiquitin ligase activity, a heterodimer of RING finger domains of BRCA1 and BARD1 has considerable activity. BARD1 is a RING domain protein shown in a two-hybrid screen to interact with BRCA1 RING domain [41] . Intriguingly BARD1 is also mutated in breast and ovarian tumours, albeit infrequently [42] . Although these results are highly suggestive, we still await the finding of physiological targets of BRCA1-BARD1 ubiquitination; one potential target, the FANCD2 protein, was discussed above.
The end in sight?
An intriguing addition to the list of putative functions for the BRCA1 protein has been a possible role in mRNA processing. Kleiman and Manley [43] have shown that BARD1 interacts with the polyadenylation factor CstF and inhibits 3′ end processing of mRNA precursors. A more recent study by the same group [44] showed that DNA damage by either UV or hydroxyurea could inhibit polyadenylation in vitro and that this inhibition was mediated via the BARD1-CstF interaction. Regulation of polyadenylation is thought to play an important role in cell growth control [45, 46] . A complex containing BRCA1, BARD1 and CstF increases transiently following DNA damage and inhibits polyadenylation. This may prevent inappropriate RNA processing and production of aberrant transcripts. Both BRCA1 and BARD1 can associate with the RNA polymerase II complex [47, 48] which is necessary for efficient 3′ cleavage of mRNA; Kleiman and Manley [43] propose a model whereby BRCA1 and/or BARD1, via their RING domain, control degradation of RNA polymerase II by ubiquitination. A role for BRCA1 in polyadenylation is a previously unsuspected one. BRCA1-BARD1 may be recruited to sites of stalled transcription as part of a transcription-coupled DNA repair process [3] . Absence of a functional BRCA1-BARD1 complex might cause dysregulation of gene expression and perhaps contribute to tumour progression.
Chipping away at BRCA function
The simultaneous analysis of the expression of thousands of genes by microarrays has started to contribute to our understanding of how mutations in BRCA1 and BRCA2 can lead to tumour susceptibility and loss of cell growth control. Using this technology, Harkin et al. [49] showed that induction of BRCA1 expression can lead to changes in expression of various genes implicated in growth control such as GADD45 and EGR1. This led to the identification of a specific pathway -the JNK/SAPK pathway -activated during BRCA1-induced apoptosis. Similarly
MacLachlan et al. [50] identified a number of genes whose transcription was differentially affected by expression of BRCA1. Some of these genes are obviously involved in the control of cellular proliferation (Cyclin B1, PIN1, PCNA) whereas others have been implicated in responding to DNA damage (GADD45, GADD153). However, it should be noted that both of these studies were based on BRCA1 overexpression in a BRCA1 wild-type cellular background; whether this is physiologically relevant to the situation in a BRCA1 null tumour is not clear.
cDNA microarrays have also been used to show that different groups of genes are expressed by tumours arising in patients carrying mutations in either BRCA1 or BRCA2 [51] . The authors could quite accurately predict from which genetic mutation different tumours had arisen by the expression profiles of relatively small groups of genes. A set of 9 genes could be used to distinguish tumours that did or did not carry BRCA1 mutations and a set of 11 genes could be used to distinguish tumours that carried BRCA2 mutations, though to a less statistically significant extent. Follow-up immunohistochemical analysis using tissue arrays confirmed at the protein level that cyclin D1 was more highly expressed in BRCA2 tumours than in BRCA1 tumours [51] .
The above study demonstrates how cDNA and tissue arrays will be important tools in not just the research laboratory but also in a clinical setting, both diagnostically and therapeutically. However, it also raises some questions about the experimental design of microarray experiments [52] . Gene expression microarray experiments generate vast quantities of data and there can be tremendous variation within these data sets, especially when comparing samples such as panels of tumours. The scientific community is still determining the best ways to analyse such large data sets and is improving algorithms for clustering covarying sets of genes. Therefore, as much variation as possible, particularly in pathological features, needs to be removed from the samples being compared. Obviously, this is not always possible and so larger patient or sample numbers will be needed to validate the changes seen in the experiments of Hedenfalk et al. [51] . However, it is
Review BRCA proteins R671 
Promiscuous partner in transcription
The analysis of global gene expression changes using microarrays has added to the already considerable literature on the role of BRCA1 and BRCA2 in the regulation of transcription [53] . BRCA1 and BRCA2 regulate transcription in concert with a number of cofactors including the histone acetylases, deacetylases and associated proteins HDAC, CBP/p300, CtIP and P/CAF, as well as RNA polymerase II holoenzyme [53] . Recently, BRCA1 was shown to interact directly with a novel sequence-specific DNA binding protein, ZBRK1 [54] . GADD45, a gene which has been shown to be a target of BRCA1 transcriptional control in microarray experiments [49, 50] , is repressed by ZBRK1. Underscoring the significance of the interaction, breast cancer-derived BRCA1 mutations that disrupt the interaction between BRCA1 and ZBRK1 also block the corepressor activity of the complex [54] .
Paradoxically however, BRCA1 overexpression caused an induction of GADD45 in previous studies. So how does this tally with a role for BRCA1 as a corepressor of GADD45?
The authors [54] suggest a model whereby BRCA1 and ZBRK1 repress GADD45 transcription in the uninduced state, but following a signal such as DNA damage leading to increased BRCA1 phosphorylation or protein levels, there is derepression of GADD45 gene transcription. Intriguingly, this suggests that BRCA1 might play a role in both corepression and coactivation of the same gene; it will be interesting to determine which other genes fall under this putative dual transcription activity. Other genes encoding potential ZBRK1 binding motifs have been identified [54] , including GADD153, Ki-67, Bax and p21, all of which may be targets of BRCA1 transcriptional control.
Another interaction that supports a role for BRCA1 in transcriptional regulation is that with the signal transduction and activator of transcription protein, STAT1 [55] . BRCA1 binds to the STAT1a transcriptional activation domain which leads to the induction of a family of interferongamma regulated genes. More recently it has been reported that over-expression of BRCA1 in prostate cancer cells can cause activation of not only STAT3 but also the upstream activators of STAT3, JAK1 and JAK2 [56] . Interestingly, groups of interferon-induced genes have been shown by a microarray approach to undergo substantial co-variation in expression across a panel of breast tumours [57, 58] . Interferons are important regulators of cell growth and apoptosis and therefore this role of BRCA1 could be important in tumour progression.
Tumours arising in BRCA1 mutation carriers are frequently negative for the estrogen receptor. Intriguingly, it has been reported that BRCA1 can inhibit estrogen receptor signalling. Overexpression of BRCA1 blocks estrogen receptor-α mediated activation of an estrogenresponsive reporter and inhibits the transcriptional activity of the carboxy-terminal domain of estrogen receptor-α [59] . Possibly this is mediated by direct interaction of the receptor and BRCA1 [60] . Others have suggested that the androgen receptor is transcriptionally coactivated by BRCA1 and also physically interacts with it [61, 62] . It is not clear yet how BRCA1 might inhibit signalling as part of an estrogen receptor-α or androgen receptor transcriptional cascade. And the promiscuity of interactions involving BRCA1 may raise questions about specificity. However the suggestion of a role for BRCA1 in steroid hormone signalling is seductive as it may help to explain the tissue-specific nature of the tumours caused by BRCA1 mutation.
BRCA1 branches out
Another surprising development has been the demonstration that BRCA1 can bind directly to DNA with high affinity but in a sequence non-specific fashion [63] . Recombinant BRCA1 binds DNA as a multimer and in doing so generates DNA loops. BRCA1 has higher affinity for (a-f) Electron micrographs of BRCA1 bound to linear plasmid DNA at the base of DNA loops. From [63] .
branched DNA than linear molecules ( Figure 4) . As a result of this DNA binding, BRCA1 inhibits the exonuclease activity of the Mre11-Rad50-Nbs1 complex that has been implicated in double-stranded break repair processes, particularly that of non-homologous end joining [64] . As mentioned above, BRCA1 deficient mouse cells exhibit a decrease in the repair of double-stranded DNA breaks by homologous recombination and an increase in non-homologous end joining [23] . Paull et al. [63] speculate that the inhibition of the exonuclease activity of the Mre11-Rad50-Nbs1 complex normally provided via BRCA1 DNA binding might explain the increase in nonhomologous end joining seen in Brca1 deficient cells.
Parvin has suggested a model [65] (Figure 5 ) incorporating the new data on DNA binding by BRCA1 with previous results suggesting a role for the protein in transcriptioncoupled repair [3] . According to this model BRCA1 is associated with the RNA polymerase II holoenzyme which becomes arrested at sites of DNA damage. He proposes that this results in the ubiquitination and degradation of RNA polymerase II by the BRCA1-BARD1 ubiquitin ligase heterodimer. This then might lead to dissociation of the complex leaving BRCA1 bound to the site of the lesion. BRCA1 would then recruit other factors, such as the Mre11-Rad50-Nbs1 complex or RAD51, to repair the DNA damage. Although this model accounts for some observations, it awaits compelling experimental support.
Complex city
Much of what we know about BRCA1 and BRCA2 has been derived from descriptions of the various multiprotein complexes in which the proteins are found. One of the first complexes with which BRCA1 was found to be associated was the RNA polymerase II holoenzyme, a multi-subunit complex of over 1 MDa [48] . In addition, BRCA1 has been shown to associate directly with the Mre11-Rad50-Nbs1 complex [66] which is responsible for end-processing of double-strand breaks during DNA repair [64] . More recently BRCA1 has been shown to be associated with other large complexes involved in DNA repair or chromatin remodelling.
The BRCA1 associated genome surveillance complex, BASC [67] , is larger than 2 MDa and contains at least 15 subunits. As well as BRCA1, the complex contains the products of the Bloom's syndrome and ataxia telangiectasia (ATM) disease genes. Four subcomplexes implicated in DNA repair -Mre11-Rad50-Nbs1, the MSH2-MSH6 heterodimer, the MLH1-PMS2 heterodimer and DNA replication factor C -are present in BASC. The presence of mismatch repair proteins in BASC provides support for the suggestion that BRCA1 is important for transcription coupled repair of oxidation-induced DNA damage [3] . Alternatively, mismatch repair proteins have been shown to have a role in homology searching during double-strand break repair [68] and this may also explain their presence in BASC.
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Figure 5
Model of the role of BRCA1 in transcriptioncoupled repair. An RNA polymerase II holoenzyme-BRCA1-BARD1 transcription complex reaches damaged DNA, depicted as a flap, where it arrests. At this point the BRCA1-BARD1-E3 ubiquitin ligase complex becomes active leading to the ubiquitination of RNA polymerase II and its degradation. BRCA1 remains bound to the DNA where it recruits a complex which repairs the lesion. Modified from [65] . [69] [70] [71] . As many of the proteins in BASC are involved in repairing DNA damage that can occur at replication forks, BRCA1, by association, may also participate in the resolution of inappropriate DNA structures during post-replicational repair.
As well as being associated with BASC and the RNA polymerase II holoenzyme, BRCA1 is also a member of a large SWI/SNF-related complex which has chromatin remodelling properties [72] . In particular a direct interaction was demonstrated between BRCA1 and the bromo-domain containing protein BRG1. Additionally, this provides a link between BRCA1 and cell cycle progression as BRG1 has been shown to interact with the critical cell cycle regulator RB [73] . How does this tally with putative functions for the BRCA1 protein? Does BRCA1 regulate transcription via modulation of chromatin structure or is its function in such a complex to allow access for the DNA repair machinery? Interestingly, the BRCA1-chromatin remodelling complex does not contain the Mre11-Rad50-Nbs1 complex, other identified BASC components or RNA polymerase II. Perhaps the methods of purification are critical here. BASC was purified by immunoprecipitation from unfractionated HeLa nuclear extracts [67] . The SWI/SNF complex on the other hand was affinity purified following nuclear extract fraction by column chromatography [72] . Association with the RNA polymerase II holoenzyme was shown by antibody probing of RNA polymerase II-containing fractions from whole cell extracts which had undergone column chromatography [48] . These protocols each yielded different complexes consisting of non-overlapping sets of subunits, all containing BRCA1; it seems possible that the different complexes may be present in the cell simultaneously.
Complexes containing BRCA2 have been less forthcoming but recently BRCA2 was also shown to be a member of a large, 2 MDa complex [74] . One of the components of this complex is BRCA2-associated factor 35kDa, or BRAF35. BRAF35 was identified as a structural, non-specific, DNA binding protein, an activity conferred by the high mobility group -HMG -domain of the protein. Direct interaction of BRCA2 and BRAF35 was demonstrated in vitro and both proteins share very similar patterns of expression during embryogenesis with the highest levels in rapidly dividing cells. Immunoflourescent staining of HeLa cells with antibodies to BRAF35 localised the protein to mitotic chromosomes during early chromosome condensation. At the onset of the metaphase to anaphase transition, this localisation is lost. BRCA2 is colocalised with these mitotic chromosomes suggesting a role in cell cycle progression; indeed microinjection of antibodies to BRAF35 or BRCA2 into synchronised HeLa cells delayed entry into mitosis.
One feature of the HMG domain is an affinity for DNA with sharp bends [75] , this prompted the authors [74] to look at the DNA binding activity of BRAF35. Gel-shift assays showed that BRAF35 bound specifically to cruciform, or four-way junction, DNA. Such unusual DNA structures are created during recombination-mediated repair and after DNA adduct formation; it may be that BRAF35 serves to target BRCA2 to sites of DNA damage.
Summary and conclusions
So what are we to make of these findings of disparate and apparently unrelated functions for BRCA proteins? Well perhaps for BRCA1 part of the solution lies in the ubiquitination function of the BRCA1 and BARD1 heterodimer. Similar models, in which the ubiquitin ligase activity is a key feature, have been put forward for the role of BRCA1 in both polyadenylation [44] and DNA repair [64] . One could imagine scenarios where other roles of BRCA1, for example in transcriptional regulation, could be partly ascribed to this enzymatic activity. Perhaps the presence of BRCA1 in a large number of protein complexes indicates that it has a generalised role regulating the abundance of individual proteins or the stoichiometry of complexes. This might explain the rather pleiotropic cellular consequences of loss of the gene. Given the flurry of activity in the field it seems very likely that even more new functions for BRCA1 and BRCA2 proteins will be forthcoming over the next few years. We already have several plausible explanations of how loss of these genes leads to tumorigenesis but whether these actually operate in a woman carrying a BRCA mutation is still unclear. The key question of why tumours arising through BRCA mutations are relatively specific to the breast and ovary is also unresolved.
